ArticleEuropean heart journal. Case reports2025
A case of cardiac involvement in Fabry disease caused by the p.D313Y variant of the GLA-gene.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the GLA gene, leading to progressive sphingolipid accumulation in various tissues, including the heart. Cardiac manifestations often include left ventricular hypertrophy (LVH), myocardial fibrosis, and conduction abnormalities. The p.D313Y variant of the GLA gene is considered a milder mutation and may present with milder or without classical FD symptoms. Case summary: We report a 54-year-old male presenting with persistent fatigue and dry cough following a mild viral infection. Initial work-up showed premature atrial and ventricular contractions, stress-induced ischaemia on myocardial perfusion imaging, and mildly reduced left ventricular ejection fraction (EF). Cardiac magnetic resonance imaging (CMR) revealed focal late gadolinium enhancement (LGE) in the basal inferolateral myocardium, with normal native T1 (nT1) values. Follow-up imaging demonstrated progressive myocardial changes, including further EF reduction and decreasing nT1 values. These findings raised suspicion for FD. Genetic testing confirmed the p.D313Y variant in the GLA gene, and enzymatic analysis showed mildly reduced α-galactosidase A activity. Discussion: This case highlights myocardial involvement in p.D313Y-associated Fabry disease (vFD) in the absence of LVH or classical symptoms. CMR, particularly native T1 mapping, proved useful in identifying early myocardial changes. The findings suggest that even patients with vFD and no LVH may develop significant cardiac pathology. This case emphasizes the importance of considering FD in patients with unexplained cardiac symptoms and unremarkable coronary findings. Further research is needed to assess the potential benefits of early intervention with enzyme replacement or chaperone therapy in vFD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.